Patents by Inventor Tristin E Rose

Tristin E Rose has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230152226
    Abstract: An optical sensor is used to detect a target in a sample liquid. The optical sensor has an optical sensing layer including, in the same layer, a fluorescent reporter, a fluorescent reference, and an optical isolating reagent. The optical sensing layer has an outer surface that contacts the sample liquid and an opposing surface through which a light source irradiates the optical sensing layer with excitation light, and a detector detects fluorescence emitted from within the optical sensing layer. The optical isolating reagent reduces the amount of (i) excitation light that passes through the optical sensing layer and reaches the sample liquid and (ii) background fluorescence that is emitted within the sample liquid and passes back through the optical sensing layer to the detector. Accordingly, the optical reporter and optical reference fluorescence can be detected with higher signal to noise ratios than in the absence of the optical isolating reagent.
    Type: Application
    Filed: September 20, 2022
    Publication date: May 18, 2023
    Inventors: Stephen V. Fiacco, Amanda N. Bruin, Matthew J. Willmore, Tristin E. Rose, Guillermo Martinez-Ariza, Keerthi Boddupally
  • Publication number: 20230116602
    Abstract: The present disclosure provides compounds, such as compounds of Formula I, and compositions that are MCL1 inhibitors.
    Type: Application
    Filed: October 2, 2020
    Publication date: April 13, 2023
    Inventors: Brendan M. O' Boyle, Emma L. Baker-Tripp, Corey M. Reeves, Kevin C. Yang, Tristin E. Rose, Justin A. Hilf, Brian M. Stoltz, Michael D. Bartberger, Oliver C. Loson, Martina S. McDermott, Neil A. O'Brien, Dennis Slamon
  • Publication number: 20220227738
    Abstract: The invention relates to compounds of Formula I, and pharmaceutically acceptable salts thereof, and methods of making and using the same. The compounds of the invention are effective in inhibiting KRAS protein with a G12C mutation and are suitable for use in methods of treating cancers mediated, in whole or in part, by KRAS G12C mutation.
    Type: Application
    Filed: May 20, 2020
    Publication date: July 21, 2022
    Inventors: Justin A. Hilf, Tristin E Rose, Michael D. Bartberger, Brendan M. O'Boyle, Corey M. Reeves, Oliver C. Loson, Brian M. Stoltz, Martina S. McDermott, Neil A. O'Brien, Dennis Slamon